US Patent Issued to Genentech on Dec. 9 for "Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodies" (California Inventors)

ALEXANDRIA, Va., Dec. 9 -- United States Patent no. 12,492,261, issued on Dec. 9, was assigned to Genentech Inc. (South San Francisco, Calif.).

"Subcutaneous dosing of anti-CD20/anti-CD3 bispecific antibodies" was invented by Chi-Chung Li (South San Francisco, Calif.), Carol Elaine O'Hear (South San Francisco, Calif.), Hong Wang (South San Francisco, Calif.), Brendan Christian Bender (South San Francisco, Calif.) and Iraj Hosseini (South San Francisco, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the i...